Klivira
Request demo

Streamlining Lantus Prior Authorization for Gastroenterology Practices

Managing Lantus prior authorization for gastroenterology patients, alongside the specialty’s extensive PA burden, requires robust automation to maintain revenue cycle efficiency and ensure patient access to care.

Gastroenterology practices navigate a complex landscape of prior authorizations, from high-cost biologics to advanced imaging and procedures. While Lantus (insulin glargine) is not a primary GI medication, patients seen by gastroenterologists frequently have comorbidities such as diabetes, making its prior authorization a relevant workflow consideration for the practice’s PA team. Klivira provides a unified platform to manage both general high-volume drug PAs and the intricate, specialty-specific requirements of GI care.

The Intersection of Lantus and Gastroenterology Patient Care

While gastroenterologists do not typically prescribe Lantus for primary GI conditions, patients with complex GI disorders often present with comorbidities requiring medications like insulin. Lantus remains a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans, meaning GI practices managing these patients may still encounter its PA requirements. Efficiently processing these authorizations is crucial to avoid care delays and administrative backlogs.

Core Prior Authorization Categories in Gastroenterology

The primary PA burden for gastroenterology practices centers on a distinct set of high-cost medications and procedures. Klivira's platform is engineered to address these specific challenges, integrating payer policy logic for each category. Key PA-triggering categories include IBD biologics, Hepatitis C direct-acting antivirals, advanced imaging, and specific endoscopic procedures.

Critical Documentation for GI-Specific Prior Authorizations

  • **For IBD Biologics:** Diagnosis confirmation (endoscopic, imaging, histologic), disease severity assessment (Mayo score for UC, CDAI or Harvey-Bradshaw for Crohn's), prior conventional-therapy trial, prior biologic experience, TB and hepatitis screening pre-initiation, step therapy compliance.
  • **For Hep C DAAs:** Genotype, fibrosis stage (FibroSure, transient elastography, biopsy), prior-treatment history, coinfections (HIV, HBV), drug-drug interaction review.
  • **For Advanced Imaging:** Clinical question, prior imaging history, conservative-evaluation workup completion.
  • **For Capsule Endoscopy:** Prior workup including upper GI series or EGD, indication (obscure GI bleeding, evaluation of small bowel for IBD, polyp surveillance), payer-specific medical necessity criteria.
  • **For Specialty Functional-GI Drugs:** Diagnosis criteria (Rome criteria for IBS), prior conservative-therapy trial documentation.

Common Denial Reasons Impacting Gastroenterology Practices

Denials in gastroenterology often stem from specific gaps in clinical documentation or non-adherence to payer step therapy protocols. For IBD biologics, common reasons include failure to document prior conventional therapy, missing disease severity scores, or lack of required pre-biologic screenings. For Hep C DAAs, fibrosis-stage documentation gaps or misclassification of treatment status are frequent issues. Klivira's intelligent workflows are designed to proactively identify and flag these requirements, minimizing avoidable denials.

Klivira's Comprehensive Approach to GI Prior Authorization

Klivira’s platform is purpose-built to navigate the unique demands of gastroenterology prior authorization. We automate the complex logic for IBD biologic sequencing, integrate treatment-status classification from EMR medication history, and streamline Hep C DAA workflows. Our system also manages periodic re-authorizations for chronic GI treatments and intelligently routes medical-vs-pharmacy benefit claims for biologic agents, ensuring comprehensive coverage for all patient medications, including high-volume drugs like Lantus.

Frequently asked questions

Why would a gastroenterology practice encounter Lantus prior authorizations?

Gastroenterology practices treat patients with complex health profiles, who often have comorbidities like diabetes. While Lantus is not a GI medication, if a GI patient is prescribed Lantus by another provider, the GI practice's PA team may still need to manage its authorization as part of the patient's overall care plan and medication list.

What are the highest-volume PA categories for GI practices?

The highest-volume prior authorization categories for gastroenterology practices typically include biologics for inflammatory bowel disease (IBD) such as Humira, Stelara, Skyrizi, and Entyvio, as well as various procedures and advanced imaging studies.

How does Klivira handle step therapy for GI biologics?

Klivira's platform incorporates ACG and AGA guideline-aware step therapy logic for IBD biologic sequencing. This ensures that authorization requests align with payer requirements for prior conventional therapy trials or specific biologic agent sequencing, minimizing denials related to step therapy non-compliance.

Can Klivira integrate with our EMR for GI PA workflows?

Yes, Klivira offers robust EMR integration capabilities, including SMART on FHIR, to seamlessly pull patient data, medication histories, and diagnostic results relevant for prior authorization. This automation reduces manual data entry and improves the accuracy of PA submissions for gastroenterology workflows.

Does Klivira support re-authorization for chronic GI conditions?

Absolutely. Klivira provides a dedicated periodic re-authorization workflow for chronic treatments common in gastroenterology, such as IBD biologics, which often require re-authorization every 6 or 12 months. This ensures continuous coverage and reduces administrative burden for ongoing therapies.

Related coverage

Other lantus prior authorization by payer

Other lantus prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo